Literature DB >> 16303714

Perinatal management of a preterm neonate affected by hyperprostaglandin E2 syndrome (HPS).

Martin Kömhoff1, Ismail Tekesin, Melanie Peters, Andreas Leonhard, Hannsjörg W Seyberth.   

Abstract

BACKGROUND: Neonates affected by hyperprostaglandin E(2) syndrome (HPS) present with severe polyuria. Both urinary losses as well as prostaglandin synthesis inhibitors may precipitate acute renal failure (ARF). AIM: Our goal was to maintain euvolaemia by replacement of urinary losses. PATIENT: Our patient was born prematurely with a family history typical of HPS. Urinary salt and water losses and PGE(2) excretion were determined in 2- to 4-h intervals. Salt and water were replaced accordingly.
RESULTS: Within the first 48 h, urinary losses and PGE(2) increased continuously to 50 ml/kg/h and 374 ng/h/1.73 m(2), respectively. Following exposure to 0.05-0.5 mg/kg/d indomethacin, urinary output decreased steadily to 10-15/ml/kg/h.
CONCLUSION: In euvolaemic preterm neonates with HPS and the need for excessive replacement of salt and water, inhibition of renal PGE(2) excretion with indomethacin effectively reduces polyuria and natriuresis without acutely compromising renal function.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16303714     DOI: 10.1080/08035250510043897

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  3 in total

Review 1.  Pathophysiology and clinical presentations of salt-losing tubulopathies.

Authors:  Hannsjörg W Seyberth
Journal:  Pediatr Nephrol       Date:  2015-07-16       Impact factor: 3.714

Review 2.  Bartter- and Gitelman-like syndromes: salt-losing tubulopathies with loop or DCT defects.

Authors:  Hannsjörg W Seyberth; Karl P Schlingmann
Journal:  Pediatr Nephrol       Date:  2011-04-19       Impact factor: 3.714

3.  Primary molecular disorders and secondary biological adaptations in bartter syndrome.

Authors:  Georges Deschênes; Marc Fila
Journal:  Int J Nephrol       Date:  2011-09-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.